

ACTION REQUIRED

Health Canada Approved - Apheresis Platelets Psoralen-treated and
Apheresis Platelets PAS-E Added

Customer Letter # 2023-13

2023-06-05

Dear Colleagues:

Further to Customer Letter [2022-34](#), Health Canada has approved the implementation of Apheresis Platelets Psoralen-treated and Apheresis Platelets PAS-E Added.

Component name	Abbreviation
Apheresis Platelets Psoralen-treated	APPT
Apheresis Platelets PAS-E (Platelet additive solution) added (not pathogen reduced)	AP in PAS

Previous challenges affecting the supply chain availability of critical supplies required for the pathogen reduction process have improved but may still require future adjustments to our implementation timeline if availability changes. Canadian Blood Services (CBS) understands that shifting timelines can adversely affect hospital operations and will strive to give accurate timelines and timely notifications.

Estimated implementation timeline by site (subject to change):

Production Site	APPT & AP in PAS implementation timelines
Ottawa	June 12, 2023
Winnipeg	October 23, 2023
Dartmouth	December 11, 2023
Calgary	January 22, 2024
Regina	February 12, 2024
St. John's NL	March 11, 2024
Vancouver	April 15, 2024
Brampton	May 6, 2024
Edmonton	TBA
Saint John NB	TBA

Circular of Information (COI)

Please review the COI for component indications, contraindications, warnings, and precautions. The most current versions of the Circular of Information can be found at <https://www.blood.ca/en/hospital-services/products/component-types/circular-information>. COIs for APPT and AP in PAS are expected to be posted no later than June 12, 2023.

Action required for all hospitals:

All hospitals must prepare for implementation of these platelet components. Share the implementation updates, component information and resource links (see next paragraph) with physicians/nursing and affected staff in your hospital. Please update LISs with new codes: [CL 2022-34 Attachment 1](#). CBS manages a national platelet inventory so **hospitals could receive psoralen-treated platelets even if the local Canadian Blood Services production site has not yet implemented** the pathogen reduction process.

Please visit

- [FAQ: Information for health professionals on apheresis platelet psoralen-treated \(APPT\) and untreated apheresis platelet in PAS-E | Professional Education \(blood.ca\)](#)
- [Clinical Guide Chapter 19: Pathogen-reduced platelets](#) for educational materials, including a Clinical Guide providing detailed information about these platelet components.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the “Hospital Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

David Howe
Director, Supply Chain Process Management